Keyphrases
Action Program
9%
Adjuvant Chemotherapy
6%
American Women
9%
Ancestry-specific
9%
Anthracyclines
9%
Brain Metastases
9%
Breast Cancer
100%
Breast Cancer Diagnosis
9%
Breast Cancer Patients
14%
Breast Cancer Risk
7%
Breast Cancer Subtypes
22%
Breast Cancer Survival
9%
Breast Cancer Treatment
9%
Cancer Clinical Trials
9%
Cancer Control
11%
Cancer Therapy
9%
Capecitabine
9%
Carcinoma in Situ
9%
CD-8
6%
CD163
9%
CD4+
7%
CD68
6%
Clinical Trials
12%
Colombia
7%
Confidence Interval
10%
Dexamethasone Treatment
9%
Disease-free Survival
9%
Docetaxel
9%
Early Breast Cancer
17%
EORTC
9%
Esperanza
9%
Estrogen Receptor-positive
9%
Everyday Practices
9%
Gene Expression Profiling
9%
Genetic Epidemiology
9%
Genomic Risk
9%
Glioblastoma
19%
Hazard Ratio
6%
HER2-positive
9%
Hereditary Breast Cancer
9%
Hereditary Ovarian Cancer
9%
HMG-CoA Synthase
7%
Hormone Receptor-negative
7%
Human Epidermal Growth Factor Receptor
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
19%
Immuno-oncology
28%
Indigenous Americans
22%
Integrated Missions
9%
Interobserver Agreement
9%
Intestine
9%
Ketogenesis
9%
Latin American Studies
9%
Latin American Women
9%
Latinas
7%
Letrozole
9%
Liver
9%
LORELEI
9%
Malignancy
10%
MammaPrint
6%
Metastatic Breast Cancer
9%
Mexico
7%
MGMT Promoter Methylation
6%
MicroRNA
9%
MINDACT
9%
Neoadjuvant
11%
Neoadjuvant Chemotherapy
10%
Neoadjuvant Therapy
11%
Newly Diagnosed
9%
Odds Ratio
12%
Oncology Biomarkers
28%
Overall Survival
14%
Pathogenic Variants
9%
Pathologist
12%
Peru
15%
Peruvian
28%
Phase II Trial
18%
PIK3CA mutation
12%
Pineal Region
9%
Placebo
9%
Placebo-controlled
9%
Postmenopausal Women
9%
Prognostic Factors
10%
Prognostic Implications
9%
Prognostic Information
11%
Programmed Death-ligand 1 (PD-L1)
12%
Radiotherapy
7%
Randomized Double-blind
9%
Regulatory Genes
9%
Residual Cancer Burden
9%
Residual Disease
19%
Risk Management
10%
Risk Management Framework
9%
Stromal Tumor-infiltrating Lymphocytes
19%
Suckling Mice
9%
Taselisib
9%
Triple Negative
10%
Triple-negative Breast Cancer
25%
Tumor
10%
Tumor-infiltrating Immune Cells
18%
Tumor-infiltrating Lymphocytes
64%
Medicine and Dentistry
Biological Marker
37%
Brain Metastasis
9%
Breast Cancer
82%
Cancer
9%
Cancer Control
7%
Cancer Therapy
9%
Carcinoma in Situ
9%
Clinical Trial
20%
Disease
8%
Estrogen Receptor
11%
Exon
9%
Glioblastoma
10%
Immunocompetent Cell
10%
Immunoglobulin
28%
Letrozole
9%
Malignant Neoplasm
14%
Metastatic Breast Cancer
9%
microRNA
9%
Minimal Residual Disease
20%
Neoadjuvant Chemotherapy
10%
Neoadjuvant Therapy
11%
Neoplasm
19%
Oncology
29%
Pathologist
12%
Placebo
9%
Postmenopause
9%
Prognostic Factor
10%
Programmed Death-Ligand 1
9%
Radiation Therapy
6%
Stromal Tumor
19%
Taselisib
9%
Triple Negative Breast Cancer
26%
Tumor Infiltrating Lymphocyte
73%